MT4 vs MT5: Pros and Cons for Traders
BiFu Research · 2026-06-20 · 2 min read
Table of contents
MT4 and MT5 are the world's most widely used forex trading platforms. This article provides a comprehensive comparison of their key features, advantages, and limitations to help you make an informed choice.
MT4 and MT5 are currently the two most widely used forex trading platforms globally. Although both are developed by MetaQuotes, each has unique features suited to different types of traders.
Advantages of MT4
Since its launch in 2005, MT4 has accumulated a large user base, with rich community resources and third-party indicators. It is optimized for forex trading with a clean and efficient interface. It supports Expert Advisors (EAs) developed in MQL4, a mature ecosystem of automated tools, and most brokers support MT4, offering a wide range of choices.
Limitations of MT4
MT4 has a more limited range of asset classes, mainly focusing on forex and CFDs; fewer chart timeframes (only 9 standard timeframes); and does not support Depth of Market (DOM) functionality.
Advantages of MT5
MT5 covers multiple asset classes including forex, stocks, futures, and options; offers 21 chart timeframes for richer analysis dimensions; includes a built-in economic calendar for tracking important economic events; supports real-time Depth of Market; and offers faster multi-currency backtesting.
Limitations of MT5
MT4 and MT5 EAs are not compatible, resulting in higher migration costs; some smaller brokers do not yet support MT5; and the learning curve is relatively steeper.
How to Choose?
If you primarily trade forex, MT4 is a time-tested, robust choice. If you want to trade diversified asset classes or need more advanced analysis features, MT5 is a more forward-looking option.
深入了解市场教育资源
MT4 and MT5 are the world's most widely used forex trading platforms. This article provides a comprehensive comparison of their key features, advantages, and limitations to help you make an informed choice.
Disclaimer
本文仅供教育与信息参考之用,不构成投资建议。交易具有风险,历史表现、示例与市场分析均不保证未来结果。
Related articles
Moderna Stock: Melanoma Trial Evidence and Cash Use
Moderna stock analysis starts with Merck's August 19, 2026 melanoma trial update: recurrence and distant-metastasis endpoints were met, while overall survival remains under follow-up. Approval, safety, delivery and cash use still limit conclusions about commercial value and future share prices.
2026-10-09 · 10 min read
Nvidia Stock Analysis: $230 Resistance vs. $235 Billion Buyback Signal
Nvidia stock analysis separates $235 billion in buyback capacity through fiscal 2028 from evidence of sustained AI-driven earnings growth. Price support depends on actual repurchases; authorization alone does not establish a price floor.
2026-10-09 · 12 min read






